RE:SurprisedThere was a large seller puking out shares at any price someone would buy them. That seller finally ran out of shares to sell and the stock is in the process of returning to a more normal price in light of the fundamentals. Good news on positive cash generation and the cash level created the volume needed to clean up the seller. So, there is likely still more upside in the stock. We will know more about how they generated a minimum of $3 million in cash between 7/28 and 8/31once they report results but financial engineering certainly played a roll.
Momo25 wrote: Suddenly, and without any material information, the share price is skyrocketing. In less than 2 weeks, we are almost at 350% growth. What is the explanation of this surge? we don't know. It can never be the sales of the legacy drugs that made that difference. It can never be the oncology program neither, because they just started hiring candidates to go through the testing process. Positive Ebidta was counted for, for a while. It just happened before the end of the year. Without a significant revenue generation, that means they cut further in their internal costs or did some magic financial reengineering.
As usual, we don't know what happened and we don't know where the SP is heading. The push button that makes it skyrocketing is the same that can deep dive it again.